Abstract
The current view is that systemic inflammation, which is specific to all chronic inflammatory rheumatic diseases (CIRD), accelerates atherogenesis; this hypothesis is supported by the high cardiovascular (CV) morbidity and mortality rates and the high prevalence of all atherosclerosis stages and complications in CIRD patients. The assessment of traditional CV risk factors underestimates the actual risk in patients with CIRD. A comprehensive evaluation and follow-up of both traditional and non-traditional CV risk factors, as well as the correct classification of risk reduction categories are necessary. Imaging techniques (e.g. carotid intima-media thickness and flow-mediated vasodilation) can be used for the early diagnosis of endothelial dysfunction. Immunologic and metabolic markers (anti-cyclic citrullinated peptide (CCP) antibodies, IgM rheumatoid factor, circulating immune complexes, proinflammatory cytokines, TH0/TH1 lymphocytes and homocysteine) may be involved in the atherosclerotic disease development specific to CIRD. A modern therapeutic approach should include the early diagnosis of endothelial dysfunction and atherosclerosis, treatment of CIRD, specific medication designed to control atherosclerosis, changes in patient lifestyle and periodic follow-ups. The assessment and diagnosis of traditional and non-traditional CV risk factors, followed by aggressive prevention and therapy, are necessary to achieve efficient control over the inflammation, immunologic and metabolic disorders specific to CIRD.
Keywords: Atherogenesis, immune-mediated inflammatory diseases, cardiovascular risk factors, chronic inflammatory rheumatic diseases.
Current Vascular Pharmacology
Title:Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Volume: 13 Issue: 6
Author(s): Elena Rezu, Mariana Floria, Anca Grigoriu, Bogdan I. Tamba and Ciprian Rezus
Affiliation:
Keywords: Atherogenesis, immune-mediated inflammatory diseases, cardiovascular risk factors, chronic inflammatory rheumatic diseases.
Abstract: The current view is that systemic inflammation, which is specific to all chronic inflammatory rheumatic diseases (CIRD), accelerates atherogenesis; this hypothesis is supported by the high cardiovascular (CV) morbidity and mortality rates and the high prevalence of all atherosclerosis stages and complications in CIRD patients. The assessment of traditional CV risk factors underestimates the actual risk in patients with CIRD. A comprehensive evaluation and follow-up of both traditional and non-traditional CV risk factors, as well as the correct classification of risk reduction categories are necessary. Imaging techniques (e.g. carotid intima-media thickness and flow-mediated vasodilation) can be used for the early diagnosis of endothelial dysfunction. Immunologic and metabolic markers (anti-cyclic citrullinated peptide (CCP) antibodies, IgM rheumatoid factor, circulating immune complexes, proinflammatory cytokines, TH0/TH1 lymphocytes and homocysteine) may be involved in the atherosclerotic disease development specific to CIRD. A modern therapeutic approach should include the early diagnosis of endothelial dysfunction and atherosclerosis, treatment of CIRD, specific medication designed to control atherosclerosis, changes in patient lifestyle and periodic follow-ups. The assessment and diagnosis of traditional and non-traditional CV risk factors, followed by aggressive prevention and therapy, are necessary to achieve efficient control over the inflammation, immunologic and metabolic disorders specific to CIRD.
Export Options
About this article
Cite this article as:
Rezu Elena, Floria Mariana, Grigoriu Anca, Tamba I. Bogdan and Rezus Ciprian, Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150105112820
DOI https://dx.doi.org/10.2174/1570161113666150105112820 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fish Oil Supplementation: A Matter of DHA Enzymatic/Non-Enzymatic Oxidation Balance?
Current Nutrition & Food Science Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart
Current Pharmaceutical Design Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Current Drug Targets The Emerging Role of microRNA in Stroke
Current Topics in Medicinal Chemistry Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Evaluation of in-vitro Anti Diabetic Activity of a Siddha Herbo- Mineral Drug
Current Traditional Medicine Selective Removal of Macrophages in Atherosclerotic Plaques as a Pharmacological Approach for Plaque Stabilization: Benefits Vs. Potential Complications
Current Vascular Pharmacology Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews Atypical Chemokine Receptors in Inflammatory Disease
Current Molecular Medicine Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science The Synthetic and Biological Attributes of Pyrazole Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Targeted Drug Delivery for Cardiovascular and Cerebrovascular Diseases
Current Drug Targets Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Treasures Hunt in Old Mines: Terminalia chebula-Based Traditional Herbal Medicinal Products
The Natural Products Journal Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets HIF Inhibitors: New Hope for Cancer Therapy
Letters in Drug Design & Discovery Clinical Trials: How to Assess Confounding and Why So
Current Clinical Pharmacology An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Nutrition Communication in General Practice
Current Nutrition & Food Science